Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Hypertenze u dětí a mladých lidí ohrožených autosomálně dominantní polycystickou chorobou ledvin (HIYA-PKD)

3. listopadu 2026 aktualizováno: King's College London

Rodinná studie časné hypertenze u dětí a mladých lidí s rizikem autozomálně dominantní polycystické choroby ledvin

The goal of this project is to measure the prevalence of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and hypertension in the general population of children and young people at risk of ADPKD, using magnetic resonance imaging (MRI) for rapid diagnosis alongside genetic testing. The main question it aims to answer is:

What is the prevalence of hypertension in a population sample of adolescents with ADPKD?

Participants will have the following measurements performed:

  • Height and weight.
  • Blood pressure.
  • Non-invasive measurement of arterial stiffness.
  • Cardiac and renal MRI.
  • Blood sample.
  • Genetic testing.

Přehled studie

Detailní popis

INTRODUCTION Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the commonest genetic cause of chronic kidney disease. Despite being inherited, most people do not get symptoms until adulthood with mean age of chronic renal failure around 53 years. Hence, it was thought that there is no need to screen children and young people (C&YP) at risk of ADPKD until old enough to understand and agree to testing. Linked to this, imaging criteria to diagnose ADPKD mostly cover adult ages.

The validity of this 'adults only' approach is challenged by reports of hypertension in C&YP with ADPKD, affecting up to a quarter by late teens. This is important in deciding whether to change screening policy because early treatment has the potential to reduce risk of cardiovascular events long-term. Death from cardiovascular disease is still a frequent event in ADPKD families, even before reaching end-stage kidney disease. Not only does the renal damage in ADPKD affect BP and cardiovascular health but there is evidence that ADPKD causes generalised endothelial dysfunction. This provides further justification for good BP control and treatment from the earliest stages of ADPKD.

Currently, it is not known whether the estimated prevalence of hypertension in C&YP with ADPKD is overestimated because most evidence comes from specialist Paediatric Nephrology centres, where it would be expected that the more severe cases would be managed. This study will determine whether blood pressure (BP) should be screened in all C&YP at risk, as well as testing the utility of ultrasound and genetic approaches.

This proposed study will be most comprehensive assessment of blood pressure in ADPKD across all age groups. As a result, information gained may revolutionise the approach to the measurement and management of BP in medical practice, particularly in children.

PATIENT AND PUBLIC INVOLVEMENT This study has been set up to specifically consider individuals with ADPKD and so the investigators have designed this study in discussion with The PKD Charity. The investigators will continue to utilise this wealth of patient experience as this study is conducted by keeping the PKD Charity informed of progress, presenting results at patient group meetings and conferences, so that patients are able to see the work that the investigators are doing to improve their understanding of ADPKD. Any publications resulting from this work will be sent to the PKD Charity for inclusion on their website.

A trustee of the PKD charity and patient representative for ADPKD has previously reviewed patient information sheets and consent forms and as a result of helpful comments the investigators have modified the patient information sheet for children.

Lastly these proposals have been previewed as a 'theoretical potential study' on the UK PKD Charity forums: no-one expressed concerns over the study design and over 40 responders expressing immediate interest in participating.

PARTICIPANT SELECTION Source of participants

The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they have to make the first contact to express interest. Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the participant appears to be eligible for the study, the relevant Participant Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. The study coordinator will book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site

Number of participating sites involved: 3

Participant numbers: The study aims to recruit 200 C&YP in total. This generates a 95% confidence of detecting a difference between populations with hypertension prevalence of 20% (ADPKD) versus 10% with 80% power. Once they have undertaken the full BP and cardiovascular assessment (anticipated over 1-2 visits), participants will only be seen once and will not be required for further follow up. Results of genetic testing are anticipated to be available after 6-12 months.

STUDY PROCEDURES Screening Procedures

Interested participants or their parents/guardians will be able to contact the research team to find out more about the study. Enquiries about study enrolment will be fielded by the Study Co-ordinator, based at King's College London. The study coordinator can ascertain initial eligibility, whilst referring any queries to the Chief Investigator. If the subject appears to be eligible for the study, the relevant Patient Information Sheet (Parent and Adolescent/16+ versions) can be sent out to the participant and their family. All participants that undergo screening will be logged onto a screening log associated with the study.

Once eligibility is confirmed, and the participant has received the PIS, the study coordinator will contact them to book an appropriate time for the participant and their parent/guardian to attend their most convenient participating site.

Participant recruitment The study will be advertised on the PKD website, and via social media, leaflets and letters in clinic. This strategy aims to ascertain participants from an unbiased population, to ensure the scientific aims of this study are met which is to determine the true blood pressure levels in C&YP with ADPKD. In addition, using these channels publicises the study without any pressure on families/children to get involved since they now have to make the first contact to express interest.

Participants will be offered reimbursement of their reasonable expenses for them and their parent /guardian to attend their chosen participating site.

Participants and their parent/guardian will be sent age appropriate information sheets prior to their first appointment at the hospital and will have at least a week to consider their participation in the study. Written materials will be produced in English. They will be consented by a clinician when they attend for Visit 1 of the study.

Follow up Procedures When the results of the tests are ready, families will be informed of the results with a telephone consultation. If there is no evidence of ADPKD, hypertension or other novel findings, the participant will be discharged. If there is evidence of ADPKD, hypertension or another medical condition, the participant will be followed up in an NHS clinic as per standard of care.

Radiology Assessments MRI will be used to scan the kidneys for evidence of ADPKD and assess the structure and function of the heart. Both regions will be imaged in the same scan session. No contrast will be required.

MRI safety aspects will be handled by the research MRI staff in the study centre. Experienced MRI radiographers will ensure all participants have completed an MRI safety questionnaire prior to their MRI scan as per the Safety Guidelines for Magnetic Resonance Imaging Equipment in Clinical Use, MHRA, February 2021 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/958486/MRI_guidance_2021-4-03c.pdf.

END OF STUDY DEFINITION

• The date of when all the samples from all patients have been analysed.

ASSESSMENT OF SAFETY

  • No particular serious adverse events (SAEs) are expected to occur during this study.
  • Where a SAE is related to the study procedures and is an unexpected occurrence (that is, the type of event is not listed in the protocol as an expected occurrence) then it will be reported immediately upon knowledge of the event to R&D and always within 24 hours. A note will be put in the case report form (CRF) and on the participants medical notes.
  • If a SAE/AE occurs that does not require immediate reporting, this will be reported in the participant's CRF and reported to GSTT when copied into the Annual Progress Report.
  • All serious adverse events that are to be reported to R&D will be signed and dated and completed by the Investigator.
  • At other sites, the Principal Investigators at all sites must report all SAEs to the Chief Investigator first where possible. The Chief Investigator is then responsible for reporting events to the regulators/R&D as the sponsor office.

Trial Steering Committee (if applicable) N/A

Typ studie

Pozorovací

Zápis (Odhadovaný)

200

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

12 let až 17 let (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

General population of children and young people at risk of ADPKD

Popis

Inclusion Criteria:

  • Age 12 - 17 years at the time of consent
  • Able to tolerate the key study investigations (office blood pressure measurement, ambulatory blood pressure measurement, MRI and blood test)
  • Parent with confirmed clinical diagnosis of ADPKD
  • Parent (if child <16 years) or both parent and young person (if >=16 years) consents to genetic testing for ADPKD and demonstrates understanding of the implications of this.

Exclusion Criteria:

  • 18 years or above at the time of study entry
  • Unable to tolerate key study investigations
  • Presence of associated co-morbidities which make it difficult to interpret results, including congenital cardiac anomalies and known TSC-PKD1 mutations
  • Unwilling to undergo genetic testing for ADPKD

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: CASE_CONTROL
  • Časové perspektivy: CROSS_SECTIONAL

Kohorty a intervence

Skupina / kohorta
ADPKD positive

Participants with positive renal MRI and/or genetic test for ADPKD

ADPKD negative

Participants with negative renal MRI and genetic test for ADPKD

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of participants with hypertension in general population of children and young people at risk of ADPKD.
Časové okno: Day 1

Diagnosis of hypertension from clinic manual blood pressure and 24 hours ambulatory blood pressure measurement

Day 1

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of participants diagnosed with ADPKD from renal MRI compared to the number from genetic testing.
Časové okno: Day 1

Prevalence of ADPKD assessed by renal MRI compared to genetic testing

Day 1
Number of participants with cyst negative but gene positive ADPKD in this age group.
Časové okno: Day 1

Agreement between MRI and genetic testing for diagnosis of ADPKD.

Day 1
Number of participants with abnormal albuminuria in the population at risk of ADPKD.
Časové okno: Single time point

Presence of albuminuria in urine samples collected.

Single time point
Central blood pressure in young people with ADPKD compared to healthy controls
Časové okno: Day 1

Comparison between central aortic systolic and diastolic pressure (mmHg) measured by tonometry between participants with ADPKD and healthy controls

Day 1
Arterial stiffness in young people with ADPKD compared to healthy controls
Časové okno: Day 1

Comparison in carotid-femoral pulse wave velocity (m/s) between participants with ADPKD and healthy controls

Day 1

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Manish Sinha, PhD, MRCP (UK), MRCPCH, King's College London

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

15. srpna 2025

Primární dokončení (Odhadovaný)

1. března 2028

Dokončení studie (Odhadovaný)

1. března 2028

Termíny zápisu do studia

První předloženo

13. listopadu 2025

První předloženo, které splnilo kritéria kontroly kvality

20. listopadu 2025

První zveřejněno (Aktuální)

2. prosince 2025

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

4. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

3. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

IPD will not be shared beyond the study team.

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit